Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Spain / NCT06220864
Recruiting Phase 1

SNV1521 in Participants With Advanced Solid Tumors

NCT06220864 · tracked via the Priya Life Science Spain tracker
Sponsor
Synnovation Therapeutics, Inc
Phase
Phase 1
Started
2024-02-23
Last updated
2026-06-25

Condition(s) studied

Advanced Solid Tumor

Investigational drug(s) / intervention(s)

SNV1521DB-1310 →Abiraterone →Darolutamide →

SNV1521: SNV1521 is a tablet taken orally. Dose and frequency are dependent upon treatment arm.

DB-1310: DB-1310 is given as an infusion. Dose and frequency are dependent upon treatment arm.

Abiraterone: Abiraterone is taken orally. Dose and frequency are per approved prescribing instructions.

Darolutamide: Darolutamide is taken orally. Dose and frequency are per approved prescribing instructions.

Study summary

This study is testing a new medicine, SNV1521, for people with advanced cancers. The researchers want to find out if SNV1521 is safe, well-tolerated, and effective in treating solid tumors. They are investigating different doses in order to find the most effective and safe one. They are also investigating whether it can be combined with other cancer therapies.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Advanced or metastatic solid tumor malignancy * Evaluable or Measurable disease (RECIST 1.1 Criteria). * ECOG Performance Status 0 or 1. * Life expectancy \> 3 months Exclusion Criteria: * History of other malignancy within the past 2 years * Prior diagnosis of Myelodysplastic syndrome or Acute Myeloid Leukemia * Significant cardiovascular disease within 6 months * Significant gastrointestinal disease * HIV infection with a CD4+ T-cell count \< 200 cells/μL and/or a detectable viral load * Liver dysfunction

Primary outcome measure(s)

  • Safety of SNV1521 — From first dose through last dose (up to 13 months)
    Treatment emergent adverse events (TEAEs)
  • Tolerability of SNV1521 — DLTs: From first dose through completion of first cycle (28 days)
    Incidence and frequency of dose-limiting toxicities (DLTs) (Dose-escalation arm only)

Trial sites (25)

FacilityCityRegionStatus
Smilow Cancer Hospital at Yale New Haven New Haven Connecticut Recruiting
Thomas Jefferson University Philadelphia Pennsylvania Recruiting
Sarah Cannon Research Institute Nashville Tennessee Recruiting
The University of Texas M.D. Anderson Cancer Center Houston Texas Recruiting
START Center for Cancer Care West Valley City Utah Recruiting
Scientia Clinical Research Randwick New South Wales Recruiting
Princess Alexandra Hospital Woolloongabba Queensland Recruiting
Monash Health Clayton Victoria Recruiting
The Alfred Hospital Melbourne Victoria Recruiting
Linear Clinical Research Crawley Western Australia Recruiting
The Institut Jules Bordet Brussels Belgium Recruiting
University Center for Clinical Research Antwerp (UNICCRA) Edegem Belgium Recruiting
AZ Maria Middelares Ghent Belgium Recruiting
AZ Groeninge Kortrijk Belgium Recruiting
Arthur J.E. Child Comprehensive Cancer Centre Calgary Alberta Recruiting
Princess Margaret Hospital Toronto Ontario Recruiting
Institut Bergonie Bordeaux France Recruiting
UNICANCER - Centre Leon-Berard (CLB) Lyon France Recruiting
Gustave Roussy Villejuif France Recruiting
Istituto Clinico Humanitas Milan Italy Recruiting
Istituto Europeo di Oncologia (IEO) (European Institute of Oncology) Milan Italy Recruiting
NEXT Oncology - Barcelona Barcelona Spain Recruiting
Vall d'Hebron University Hospital Barcelona Spain Recruiting
The START Center for Cancer Care - Madrid - CIOCC - Hospital Universitario Madrid Sanchinarro Madrid Spain Recruiting
NEXT Oncology - Hospital Quironsalud Madrid Madrid Spain Recruiting

On this site

📄 Zytiga (abiraterone) drug profile →

Other trials for the same condition

Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET Active, not recruiting
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors Recruiting
Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors. Recruiting
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors Recruiting
A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06220864 on ClinicalTrials.gov ↗ ← All trials in Spain